Every recall we track for Harbin Jixianglong Biotech Co., Ltd. — 2 in all — plus the complaints and injury reports the public filed about them.
Harbin Jixianglong Biotech recalls specific Semaglutide doses due to incomplete process validation and bacterial endotoxin testing before distribution. This affects prescription compounding products with NDC codes 84385-106-01 to 84385-106-06.
Harbin Jixianglong Biotech recalls Semaglutide for Rx compounding due to CGMP deviations and bacterial endotoxin validation failures. Affected products include 1g, 5g, 10g, 25g, and 50g doses with specific NDCs.
